|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1050 K STREET, NW, #800 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | RESEARCH TRIANGLE PARK |
State | NC |
Zip Code | 27709 |
Country | USA |
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Sarah J. Walsh, Vice President, Federal Government Relations Tax & Pharmaceuticals |
Date | 01/19/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HR 2112 Fiscal Year 2012 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations
Act - provisions pertaining to Ryan White CARE Act, FDA funding
HR 2017 The Department of Homeland Security Appropriations Act - provisions pertaining to Customs and Border Protection
HR 2608 Fiscal Year 2012 Continuing Appropriations Act - FDA funding and related provisions
S 1599 Fiscal Year 2012 Labor-HHS-Education Appropriations; FY 2012 HHS Budget Request; provisions relating to Vaccine
Section 317 program, Ryan White CARE Act
HR 2055 Fiscal Year 2012 Consolidated Appropriations Act - provisions relating to health and trade
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S 27 Preserve Access to Affordable Generics Act - provisions related to patent settlements
HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions
relating to authorized generics
HR 2182,S 1734 Generating Antibiotic Incentives Now Act of 2011 - provisions related to antibiotics and incentives
HR 3261 Stop Online Piracy Act - provisions related to anti-counterfeiting
S 373 The Fair Prescription Drug Competition Act - provisions related to authorized generics
S 968 Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to
anti-counterfeiting
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
PL 111-148, PL 111-152Patient Protection and Affordable Care Act - ACA implementation, Independent Payment Advisory Board (IPAB), comparative effectiveness, health information technology, disease prevention/wellness, sunshine and innovation provisions
HR 2405, S 1855 Pandemic and All Hazards Preparedness Act - provisions relating to influenza vaccine innovative technologies
S 1002 Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act (SAFE DOSES)drug
safety
HR 1483 The Drug Safety Enhancement Act of 2011 - drug safety standards
HR 1930, S 1799 Access to Appropriate Immunizations for Veterans Act of 2011 - extending VA performance measure to
include all federally recommended vaccine
HR 3202 Water Protection and Reinvestment Act - provisions pertaining to pharmaceuticals in the environment
S 3397 Secure and Responsible Drug Disposal Act - provisions related to safe drug disposal
S 319 Pharmaceutical Market Access and Drug Safety Act of 2011 - provisions related to drug importation
HR 2245, S 296 Preserving Access to Life-Savings Medicines Act of 2011 - provisions related to drug shortages
HR 2939 Pharmaceutical Stewardship Act of 2011 - provisions related to drug safety
ADDENDUM/General Lobbying Issue Area - Prescription Drug User Fee Act (currently unassigned) - issues related to
reauthorization of the Prescription Drug User Fee Act
HR 2529, S 1368 Restoring Access to Medication Act - provisions relating to reimbursement of OTC drugs under flexible
spending and health savings accounts
S 1584 Drug Safety and Accountability Act of 2011- provisions related to drug safety
ADDENDUM/General Lobbying Issue Area - Federal Food, Drug, and Cosmetic Act (currently unassigned) - section related to FDA and regulation of nicotine replacement therapies
S. 1699 Prescription Drug Cost Reduction Act - provisions related to 340B and drug rebates
S. 1752 Freedom to Breath Act of 2011 - provisions relating to the removal of Essential-Use Designation for epinephrine.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 999Medicare Prescription Drug Savings and Choice Act of 2011- provisions related to Medicare Part D
HR 2190Medicare Drug Savings Act of 2011 - provisions related to Medicare Part D
HR 2248Medicare Prescription Drug Price Negotiation Act of 2011 - provision related to Medicare Part D
H.R. 3765Temporary Payroll Tax Cut Continuation Act of 2011provisions related to Medicare
S 31Prescription Drug and Health Improvement Act of 2011- provisions related to Medicare Part D
S 44Medicare Prescription Drug Price Negotiation Act of 2011- provisions related to Medicare Part D
HR 452 Medicare Decisions Accountability Act - provisions related to the Independent Payment Advisory Board (IPAB)
S 365Budget Control Act of 2011 - deficit reduction issues related to Medicare and Medicaid
S 560Medicare Prescription Drug Savings and Choice Act of 2011-provisions related to Medicare Part D
S 668Health Care Bureaucrats Elimination Actprovisions related to the Independent Payment Advisory Board (IPAB)
S 1206 Medicare Prescription Drug Savings Act of 2011- provisions related to Medicare Part D
S 1251 Medicare and Medicaid FAST Act - provisions related to Part D issues
HR 1063 Strengthening Medicare & Repaying Taxpayers Act of 2011- provisions relating to reform of Secondary Payer rules
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
HR 942American Research and Competitiveness Act of 2011provisions relating to the research and development tax credit
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
HR 3080Korea Free Trade Agreement - provisions related to intellectual property, market access and public health
Trans-Pacific Strategic Economic Partnership Agreement (TPP) - provisions related to intellectual property, market access and public health
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |